{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T10:50:18Z","timestamp":1782211818053,"version":"3.54.5"},"reference-count":36,"publisher":"Termedia Sp. z.o.o.","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pol J Pathol"],"abstract":"<jats:p>To evaluate the short-term prognosis of pediatric hepatoblastoma (HB) in relation to excision repair cross-complementation gene 1 (ERCC1) C118T single nucleotide polymorphism (SNP) and VEGF expression.&lt;br \/&gt;\nERCC1 C118T SNP and VEGF expression were detected and investigated in 31 children with HB undergoing platinum-based chemotherapy, to analyze their relationship with short-term pediatric HB prognosis.&lt;br \/&gt;\nCC (38.7%; 12\/31), CT (35.5%; 11\/31), and TT (25.8%; 8\/31) ERCC1 C118T mutation types were identified. The Kaplan-Meier survival curve analysis showed that the CC group had a better short-term prognosis than the CT + TT group (p = 0.010). VEGF was overexpressed in 14 cases (45.2%) and underexpressed in 17 cases (54.8%). The Kaplan-Meier survival curve analysis showed that the high VEGF expression group showed poorer short-term prognosis than the lower VEGF expression group (p = 0.004).&lt;br \/&gt;\nIn this study, ERCC1 C118T SNP in children with HB was mainly found to be mutant type CT + TT. Compared to wild type CC, children with the mutant type CT + TT exhibited better treatment efficacy and remission with platinum-based chemotherapy as well as better survival rates. Moreover, the short-term prognosis of children with low VEGF expression was better than in those with high expression.<\/jats:p>","DOI":"10.5114\/pjp.2019.93134","type":"journal-article","created":{"date-parts":[[2020,4,20]],"date-time":"2020-04-20T17:46:17Z","timestamp":1587404777000},"page":"304-310","source":"Crossref","is-referenced-by-count":0,"title":["Short-term prognosis of childhood hepatoblastoma in relation to ERCC1 C118T single nucleotide polymorphism and VEGF expression"],"prefix":"10.5114","volume":"70","author":[{"given":"Yuan","family":"Wen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongsheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3061","published-online":{"date-parts":[[2020,3,6]]},"reference":[{"key":"ref-1697268","doi-asserted-by":"crossref","unstructured":"Czauderna P, Lopezterrada D, Hiyama E, et al. Hepatoblastoma state of the art: pathology, genetics, risk stratification, and chemotherapy. Curr Opin Pediatr 2014; 26: 19-28.","DOI":"10.1097\/MOP.0000000000000046"},{"key":"ref-1697269","doi-asserted-by":"crossref","unstructured":"Allan BJ, Parikh PP, Diaz S, et al. Predictors of survival and incidence of hepatoblastoma in the paediatric population. HPB (Oxford) 2013; 15: 741-746.","DOI":"10.1111\/hpb.12112"},{"key":"ref-1697270","doi-asserted-by":"crossref","unstructured":"Hiyama E, Hishiki T, Watanabe K, et al. Mortality and morbidity in primarily resected hepatoblastomas in Japan: Experience of the JPLT (Japanese Study Group for Pediatric Liver Tumor) trials. J Pediatr Surg 2015; 50: 2098-2101.","DOI":"10.1016\/j.jpedsurg.2015.08.035"},{"key":"ref-1697271","doi-asserted-by":"crossref","unstructured":"Brown J, Perilongo G, Shafford E, et al. Pretreatment prognostic factors for children with hepatoblastoma \u2013 results from the International Society of Paediatric Oncology (SIOP) study SIOPEL 1. Eur J Cancer 2000; 36: 1418-1425.","DOI":"10.1016\/S0959-8049(00)00074-5"},{"key":"ref-1697272","doi-asserted-by":"crossref","unstructured":"Ismail H, Broniszczak D, Kalici\u00f1ski P, et al. Changing treatment and outcome of children with hepatoblastoma: analysis of a single center experience over the last 20 years. J Pediatr Surg 2012; 47: 1331-1339.","DOI":"10.1016\/j.jpedsurg.2011.11.073"},{"key":"ref-1697273","doi-asserted-by":"crossref","unstructured":"Malogolowkin MH, Katzenstein HM, Meyers RL, et al. Complete Surgical Resection Is Curative for Children With Hepatoblastoma With Pure Fetal Histology: A Report From the Children\u2019s Oncology Group. J Clin Oncol 2011; 29: 3301-3306.","DOI":"10.1200\/JCO.2010.29.3837"},{"key":"ref-1697274","doi-asserted-by":"crossref","unstructured":"Park CH, Bessho T, Matsunaga T, et al. Purification and characterization of the XPF-ERCC1 complex of human DNA repair excision nuclease. J Biol Chem 1995; 270: 22657-22660.","DOI":"10.1074\/jbc.270.39.22657"},{"key":"ref-1697275","unstructured":"Deng Q, Yang H, Lin Y, et al. Prognostic value of ERCC1 mRNA expression in non-small cell lung cancer, breast cancer, and gastric cancer in patients from Southern China. Int J Clin Exp Pathol 2014; 7: 8312-8321."},{"key":"ref-1697276","doi-asserted-by":"crossref","unstructured":"Xu Q, Ding YY, Song LX, et al. Correlation of UGT1A1 and ERCC1 gene polymorphisms with the outcome of combined irinotecan plus cisplatin treatment in recurrent ovarian cancer. Genet Mol Res 2015; 14: 7241-7247.","DOI":"10.4238\/2015.June.29.17"},{"key":"ref-1697277","doi-asserted-by":"crossref","unstructured":"Zhang YY, Gu KS, Wu HY, et al. Correlation of ERCC1 expression in peripheral blood lymphocytes with outcomes of patients with gastric cancer treated with oxaliplatin-based adjuvant chemotherapy. Genet Mol Res 2015; 14: 15921-15929.","DOI":"10.4238\/2015.December.7.3"},{"key":"ref-1697278","doi-asserted-by":"crossref","unstructured":"Yu X, Xiao H, Zhao B, et al. DNA repair gene ERCC1 C118T polymorphism predicts sensitivity of recurrent esophageal cancer to radiochemotherapy in a Chinese population. Thorac Cancer 2015; 6: 741-748.","DOI":"10.1111\/1759-7714.12251"},{"key":"ref-1697279","doi-asserted-by":"crossref","unstructured":"He MG, Zheng K, Tan D, et al. Association between ERCC1 and ERCC2 gene polymorphisms and susceptibility to pancreatic cancer. Genet Mol Res 2016; 15: gmr7879.","DOI":"10.4238\/gmr.15017879"},{"key":"ref-1697280","doi-asserted-by":"crossref","unstructured":"Viguier J, Boige V, Miquel C, et al. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin\/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res 2005; 11: 6212-6217.","DOI":"10.1158\/1078-0432.CCR-04-2216"},{"key":"ref-1697281","doi-asserted-by":"crossref","unstructured":"Costache MI, Ioana M, Iordache S, et al. VEGF Expression in Pancreatic Cancer and Other Malignancies: A Review of the Literature. Rom J Intern Med 2015; 53: 199-208.","DOI":"10.1515\/rjim-2015-0027"},{"key":"ref-1697282","doi-asserted-by":"crossref","unstructured":"Hsieh MC, Hsu HT, Hsiao PC, et al. Role of VEGF-C Gene Polymorphisms in Susceptibility to Hepatocellular Carcinoma and Its Pathological Development. J Clin Lab Anal 2014; 28: 237-244.","DOI":"10.1002\/jcla.21672"},{"key":"ref-1697283","doi-asserted-by":"crossref","unstructured":"Sun XY, Wu ZD, Liao XF, et al. Tumor angiogenesis and its clinical significance in pediatric malignant liver tumor. World J Gastroenterol 2005; 11: 741-743.","DOI":"10.3748\/wjg.v11.i5.741"},{"key":"ref-1697284","doi-asserted-by":"crossref","unstructured":"Aronson DC, Meyers RL. Malignant tumors of the liver in children. Semin Pediatr Surg 2016; 25: 265-275.","DOI":"10.1053\/j.sempedsurg.2016.09.002"},{"key":"ref-1697285","doi-asserted-by":"crossref","unstructured":"Kapadia RN, Zeidman MJ, Burjonrappa S. Advanced Hepatoblastoma: A Review of Current Management Strategies. Adv Res Gastroentero Hepatol 2015; 1: 555551.","DOI":"10.19080\/ARGH.2015.01.555551"},{"key":"ref-1697286","doi-asserted-by":"crossref","unstructured":"Cai S, Han K. Research on expression and importance of p53, p16 and VEGF-C in cervical cancer. J Gynecol Obstet Biol Reprod (Paris) 2015; 44: 639-645.","DOI":"10.1016\/j.jgyn.2014.07.012"},{"key":"ref-1697287","doi-asserted-by":"crossref","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"ref-1697288","doi-asserted-by":"crossref","unstructured":"Kremer N, Walther AE, Tiao GM. Management of hepatoblastoma: an update. Curr Opin Pediatr 2014; 26: 362-369.","DOI":"10.1097\/MOP.0000000000000081"},{"key":"ref-1697289","unstructured":"Hiyama E. Pediatric hepatoblastoma: diagnosis and treatment. Transl Pediatr 2014; 3: 293-299."},{"key":"ref-1697290","doi-asserted-by":"crossref","unstructured":"Czauderna P. Hepatoblastoma throughout SIOPEL trials \u2013 clinical lessons learnt. Front Biosci (Elite Ed) 2012; 4: 470-479.","DOI":"10.2741\/e392"},{"key":"ref-1697291","doi-asserted-by":"crossref","unstructured":"Perilongo G, Malogolowkin M, Feusner J. Hepatoblastoma clinical research: lessons learned and future challenges. Pediatr Blood Cancer 2012; 59: 818-821.","DOI":"10.1002\/pbc.24217"},{"key":"ref-1697292","doi-asserted-by":"crossref","unstructured":"von Schweinitz D. Hepatoblastoma: recent developments in research and treatment. Semin Pediatr Surg 2012; 21: 21-30.","DOI":"10.1053\/j.sempedsurg.2011.10.011"},{"key":"ref-1697293","doi-asserted-by":"crossref","unstructured":"Ortega JA, Douglass EC, Feusner JH, et al. Randomized comparison of cisplatin\/vincristine\/fluorouracil and cisplatin\/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: A report from the Children\u2019s Cancer Group and the Pediatric Oncology Group. J Clin Oncol 2000; 18: 2665-2675.","DOI":"10.1200\/JCO.2000.18.14.2665"},{"key":"ref-1697294","doi-asserted-by":"crossref","unstructured":"Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol 2014; 740: 364-378.","DOI":"10.1016\/j.ejphar.2014.07.025"},{"key":"ref-1697295","doi-asserted-by":"crossref","unstructured":"Usanova S, Pi\u00e9e-Staffa A, Sied U, et al. Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression. Mol Cancer 2010; 9: 475-489.","DOI":"10.1186\/1476-4598-9-248"},{"key":"ref-1697296","doi-asserted-by":"crossref","unstructured":"Gazdar AF. DNA repair and survival in lung cancer \u2013 the two faces of Janus. N Engl J Med 2007; 356: 771-773.","DOI":"10.1056\/NEJMp068308"},{"key":"ref-1697297","doi-asserted-by":"crossref","unstructured":"Sancar A, Reardon JT. Nucleotide excision repair in E. coli and man. Adv Protein Chem 2004; 69: 43-71.","DOI":"10.1016\/S0065-3233(04)69002-4"},{"key":"ref-1697298","doi-asserted-by":"crossref","unstructured":"Yanlong Y, Lei X. The association between the ERCC1\/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis. Tumour Biol 2014; 35: 2905-2921.","DOI":"10.1007\/s13277-013-1493-5"},{"key":"ref-1697299","doi-asserted-by":"crossref","unstructured":"Yin M, Yan J, Martinez-Balibrea E, et al. ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis. Clin Cancer Res 2011; 17: 1632-1640.","DOI":"10.1158\/1078-0432.CCR-10-2169"},{"key":"ref-1697300","doi-asserted-by":"crossref","unstructured":"Mccrudden KW, Hopkins B, Frischer J, et al. Anti-VEGF antibody in experimental hepatoblastoma: suppression of tumor growth and altered angiogenesis. J Pediatr Surg 2003; 38: 308-314.","DOI":"10.1053\/jpsu.2003.50099"},{"key":"ref-1697301","doi-asserted-by":"crossref","unstructured":"Dorff TB, Longmate JA, Pal SK, et al. Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer. Cancer 2017; 123: 4566-4573.","DOI":"10.1002\/cncr.30942"},{"key":"ref-1697302","doi-asserted-by":"crossref","unstructured":"Diaz-Beveridge R, Bruixola G, Lorente D, et al. An internally validated new clinical and inflammation-based prognostic score for patients with advanced hepatocellular carcinoma treated with sorafenib. Clin Transl Oncol 2018; 20: 322-329.","DOI":"10.1007\/s12094-017-1720-4"},{"key":"ref-1697303","doi-asserted-by":"crossref","unstructured":"Marsh AM, Lo L, Cohen RA, et al. Sorafenib and bevacizumab for recurrent metastatic hepatoblastoma: stable radiographic disease with decreased AFP. Pediatr Blood Cancer 2012; 59: 939-940.","DOI":"10.1002\/pbc.24171"}],"container-title":["Polish Journal of Pathology"],"original-title":[],"link":[{"URL":"https:\/\/www.polishjournalofpathology.com\/pdf-113431-136795","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.polishjournalofpathology.com\/pdf-113431-136795","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T10:32:23Z","timestamp":1782210743000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.polishjournalofpathology.com\/Short-term-prognosis-of-childhood-hepatoblastoma-in-relation-to-ERCC1-C118T-single,113431,0,2.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,6]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019]]}},"alternative-id":["113431"],"URL":"https:\/\/doi.org\/10.5114\/pjp.2019.93134","relation":{},"ISSN":["1233-9687","2084-9869"],"issn-type":[{"value":"1233-9687","type":"print"},{"value":"2084-9869","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,6]]}}}